Aurore Pharmaceuticals Private Limited (Unit I) – FDA 483, May 27, 2024
Aurore Pharmaceutical Pvt Ltd in Hyderabad, India, received a Form 483 with five observations related to significant deficiencies in their Active Pharmaceutical Ingredient (API) manufacturing operations. The inspection revealed issues with equipment cleaning and maintenance, inadequate production and process controls, insufficient investigation of failures, poor facility maintenance, and a quality control unit failing to ensure product specifications. These findings indicate a moderate level of severity concerning GMP compliance.
ID · 6a7c3efc-4945-4b60-ab7a-c603a0c3a683
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.